糖尿病患者肠道菌群特征及其相关性的系统评价

目的对糖尿病患者肠道菌群特征及其相关性进行系统评价。方法检索知网、维普、万方、PubMed、Cochrane library、Embase等数据库关于糖尿病患者肠道菌群特征及其相关性的文献,同时追踪纳入文献的参考文献,时限为2009年3月至2019年3月,采用统一提取表,由两名研究者独立按照规定的纳入排除标准进行文献提取和方法学质量评估。最后采用RevMan 5.3软件进行Meta合并,Stata 12.0软件进行亚组分析与发表性偏倚识别。结果共纳入25篇研究,合计2 209例患者。Meta分析显示:(1)糖尿病患者菌群总量(SMD=-0.30,P=0.53)、乳杆菌数量(SMD=-0.79,P=0.20)下降,拟杆菌数量(SMD=1.43,P=0.12)、梭菌数量(SMD=0.28,P=0.40)增加,差异均无统计学意义,双歧杆菌数量(SMD=-1.82,P=0.02)下降,差异有统计学意义。(2)糖尿病患者菌群Shannon指数I~2=91%,r=-0.21[-0.32,0.09],P0.05;Chao1指数I~2=0%,r=-28.17[-40.85,-15.48],P0.05;均下降。(3)拟杆菌、双歧杆菌、梭菌与空腹血糖的相关性分别为:I~2=0%,r=-0.15[-0.27,-0.03];I~2=0%,r=-1.16[-1.42,0.91];I~2=0%,r=-0.28[-0.42,-0.14],均P0.05。而乳杆菌的相关性差异无统计学意义:I~2=47%,r=-0.00[-0.30,0.29],P=0.98。(4)乳杆菌和拟杆菌与炎症因子(TNF-α、IL-6)呈负相关,乳杆菌(r=-0.43;r=-0.60),P0.05;拟杆菌(r=-0.58;r=-0.58),P0.05,差异有统计学意义。结论糖尿病患者肠道菌群总量无明显变化,但有益菌含量和多样性下降,拟杆菌、双歧杆菌和梭菌含量与血糖水平呈负相关,而乳杆菌无相关,其结果还需要大样本、高质量的研究加以论证。     

轻度支气管哮喘儿童的诱导痰菌群特征

目的探讨轻度支气管哮喘儿童的诱导痰菌群特征及临床意义。方法纳入年龄为6~12周岁于2018年11月至2019年1月在深圳市儿童医院呼吸科门诊定期复诊的轻度支气管哮喘患儿51例(哮喘组),留取诱导痰,匹配同年龄段97例健康无过敏儿童的口咽拭子作为对照。诱导痰及口咽拭子提取总DNA并扩增,对16S rRNA基因进行高通量测序并对测序结果进行生物信息学分析。结果NMDS分析结果显示哮喘组与健康对照组研究对象菌群结构存在差异;哮喘组的诱导痰菌群多样性指数(Shannon index)高于健康对照组(2.34±0.53 vs 1.87±0.50,P<0.05)。门水平分析显示,哮喘组与健康对照组的菌群均主要为厚壁菌门(38.34%vs 44.74%,P<0.05)、变形杆菌门(31.14%vs 19.78%,P<0.05)、拟杆菌门(14.59%vs 20.52%,P<0.05)、放线菌门(10.41%vs 7.85%,P<0.05)和梭杆菌门(2.82%vs 6.67%,P<0.05),但两组之间的构成比有明显差异。与健康对照组相比,在属水平上哮喘组韦荣球菌属(5.27%vs 8.96%)、普雷沃菌属(8.38%vs 17.35%)、罗斯菌属(1.50%vs 5.46%)、纤毛菌属(1.37%vs 4.39%)等非条件致病菌属比例明显下降(均P<0.05),而嗜血杆菌属(9.83%vs 6.17%)、卟啉单胞菌属(2.48%vs 1.41%)、莫拉菌属(5.66%vs 0.42%)、诺卡菌属(3.40%vs 0.00%)等条件致病菌属比例明显上升(均P<0.05)。结论尽管轻度支气管哮喘患儿已临床控制,但诱导痰内菌群仍存在结构紊乱。气道菌群紊乱可能是儿童支气管哮喘的发病机制之一。除了致病菌属外,非致病菌菌属的构成变化可能也是儿童哮喘的一个发生机制。     

土著入侵种黄帚橐吾的替代防控展望

黄帚橐吾是青藏高原高寒草场中分布最广、危害极大的优势毒草,严重影响了该地区群落结构和草地畜牧业的发展。在介绍土著入侵种和替代防控概念及相关研究进展的基础上,针对黄帚橐吾目前缺乏高效经济生态防控措施的现状,结合国内外对入侵植物进行替代防控的经验与原则,提出了对黄帚橐吾进行替代防控的生态防控设想和黄帚橐吾替代植物选用的基本原则,初步划定了防控黄帚橐吾的替代植物范围。通过引种或者驯化乡土草种,在青藏高原培育禾本科、豆科植物或者建植禾豆混播人工草地,使其具备替代防控黄帚橐吾的潜力。     

单核细胞的原代分离方法优化及其炎症激活模型的构建

为了得到高纯度高得率的单核细胞(monocyte)并分析其在血栓发生中的作用,本研究利用10位健康人的血样分离出单个核细胞(peripheral blood mononuclear cell,PBMC),并通过免疫磁珠分选来获得单核细胞,测定PBMC与单核细胞的得率。通过制备血浆中的高丰度蛋白β2GPI,并与其抗体构成抗原抗体复合物来刺激细胞培养,通过荧光定量PCR检测细胞培养基中组织因子TF和TNF-α的含量,构建单核细胞炎症激活模型。实验结果显示单核细胞的得率较高,纯度和活性较好,且β2GPI纯化效果好。荧光定量PCR结果显示,与对照组相比,添加β2GPI抗原抗体复合物的实验组TF与TNF-αmRNA表达量明显增多。本实验表明纯化的单核细胞被充分激活,在细胞水平上为研究机体炎症反应和血栓形成的分子机理提供了炎症模型。     

小麦矮秆突变体jm22d响应赤霉素处理的转录组学分析

为拓宽小麦矮秆遗传资源,利用γ射线辐照济麦22获得了一个赤霉素不敏感型矮秆突变体jm22d。株高相关性状调查结果及茎秆细胞学试验显示,jm22d株高为53±1.8 cm,比野生型（WT）低约20 cm。jm22d整株茎秆共有4节,比WT少一节且各节间长度显著小于WT。与WT相比,jm22d茎秆细胞长度缩短。赤霉素含量测定发现,jm22d叶片中赤霉素含量高于WT,而茎秆中赤霉素含量低于WT（P<0.01）,因此,jm22d株高降低与赤霉素转运途径出现异常有关。为了深入研究jm22d对赤霉素的响应机理,对jm22d和WT幼苗进行赤霉素处理,分别收取处理0（D0）、1（D1）和3 d（D3）的样品进行转录组学分析。结果表明,与WT相比,在jm22d中共筛选到696个上调和1 067个下调的表达基因,其中62个和349个基因在3个时间点分别表现为上调和下调表达。叶绿素含量测定表明,jm22d中叶绿素含量随赤霉素处理时间的延长而降低,聚类分析结果表明,差异表达基因主要富集在光合作用-天线蛋白（photosynthesis-antenna proteins,ko00196）、卟啉和叶绿素代谢（porphyrin and chlorophyll metabolism,ko00860）、亚油酸新陈代谢（linoleic acid metabolism,ko00591）等通路,因此赤霉素处理对jm22d体内叶绿素含量的积累具有抑制作用。通过KEGG分析在植物激素信号转导途径中挖掘到5个差异表达基因（TraesCS2B01G582300、TraesCS2B01G600800、TraesCS2B01G556600、TraesCS2B01G630000和TraesCS6B01G439600）参与生长素、细胞分裂素等激素代谢途径,这些基因在jm22d中显著下调,这可能是jm22d矮化的重要原因。研究结果为矮秆突变体矮化机制的解析提供了重要参考。     

基于焦磷酸测序技术建立基因编辑水稻检测方法

基因编辑技术发展迅速,但对应的检测方法较少。为寻找创建基因编辑作物适用的检测方法,以 PL3 基因编辑水稻编辑位点为靶标,有效设计了焦磷酸测序的扩增引物及测序引物,并进行有效性检测,分别利用Sequence to Analyze等程序以及SNP和AQ两种模式完成了对PL3 基因的定性和定量检测试验,建立了 PL3 基因编辑水稻编辑位点焦磷酸测序检测方法。结果表明,基于焦磷酸测序技术可以通过检测编辑位点从而将基因编辑型水稻与野生型水稻进行区分。与常规的转基因检测方法相比,该检测方法具有较好的准确性、高效性及高灵敏度等优点,在基因编辑型水稻编辑位点定性和定量检测分析方面具有很好的应用前景。     

基于植保大数据的病虫害移动智能采集新设备

为提高农作物重大病虫害发生信息自动化、智能化采集能力,全面提升监测预警水平,笔者基于大数据、人工智能和深度学习技术,研发了一款农作物病虫害移动智能采集设备——智宝,主要实现了3个方面的功能:一是病虫害发生信息自动采集上报.通过该产品进行人工拍照,可实现对田间农作物重大病虫害发生图像、发生位置、发生数量、微环境因子等数据的实时采集和上报.二是自动识别计数.基于植保大数据与人工智能技术,通过构建病虫害自动识别系统,可实现重大病虫害精准识别与分析,只要拍摄照片,即可快速、精确地识别病虫害种类,并自动计数、上报到指定的测报系统.三是自动分析判别分级.针对拍摄采集上报的重大病虫害发生信息,系统可在自动识别和计数的基础上,进一步对病虫害发生严重程度进行智能判别分级,甚至根据相关预测模型,对病虫害的发生趋势进行辅助分析预测,提出预测建议.通过2016—2019年组织多地植保机构进行试验改进,该技术产品日趋成熟,有望在未来的农作物病虫害发生信息采集和预测预报工作中推广使用.     

Rapamycin inhibits AR signaling pathway in prostate cancer by interacting with the FK1 domain of FKBP51

Reactivation of the androgen receptor signaling pathway in the emasculated environment is the main reason for the occurrence of castration-resistant prostate cancer (CRPC). The immunophilin FKBP51, as a co-chaperone protein, together with Hsp90 help the correct folding of AR. Rapamycin is a known small-molecule inhibitor of FKBP51, but its effect on the FKBP51/AR signaling pathway is not clear. In this study, the interaction mechanism between FKBP51 and rapamycin was investigated using steady-state fluorescence quenching, X-ray crystallization, MTT assay, and qRT-PCR. Steady-state fluorescence quenching assay showed that rapamycin could interact with FKBP51. The crystal of the rapamycin-FKBP51 complex indicated that rapamycin occupies the hydrophobic binding pocket of FK1 domain which is vital for AR activity. The residues involving rapamycin binding are mainly hydrophobic and may overlap with the AR interaction site. Further assays showed that rapamycin could inhibit the androgen-dependent growth of human prostate cancer cells by down-regulating the expression levels of AR activated downstream genes. Taken together, our study demonstrates that rapamycin suppresses AR signaling pathway by interfering with the interaction between AR and FKBP51. The results of this study not only can provide useful information about the interaction mechanism between rapamycin and FKBP51, but also can provide new clues for the treatment of prostate cancer and castration-resistant prostate cancer.     

Integration of high-throughput analytics and cell imaging enables direct early productivity and product quality assessment during Chinese Hamster ovary cell line development for a complex multi-subunit vaccine antigen

Mammalian cell line generation typically includes stable pool generation, single cell cloning and several rounds of clone selection based on cell growth, productivity and product quality criteria. Individual clone expansion and phenotype-based ranking is performed initially for hundreds or thousands of mini-scale cultures, representing the major operational challenge during cell line development. Automated cell culture and analytics systems have been developed to enable high complexity clone selection workflows; while ensuring traceability, safety, and quality of cell lines intended for biopharmaceutical applications. Here we show that comprehensive and quantitative assessment of cell growth, productivity, and product quality attributes are feasible at the 200–1,200 cell colony stage, within 14 days of the single cell cloning in static 96-well plate culture. The early cell line characterization performed prior to the clone expansion in suspension culture can be used for a single-step, direct selection of high quality clones. Such clones were comparable, both in terms of productivity and critical quality attributes (CQAs), to the top-ranked clones identified using an established iterative clone screening approach. Using a complex, multi-subunit antigen as a model protein, we observed stable CQA profiles independently of the cell culture format during the clonal expansion as well as in the batch and fed-batch processes. In conclusion, we propose an accelerated clone selection approach that can be readily incorporated into various cell line development workstreams, leading to significant reduction of the project timelines and resource requirements.